We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+3.57%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$288M
AUM Growth
-$30.5M
Cap. Flow
-$38.3M
Cap. Flow %
-13.28%
Top 10 Hldgs %
100%
Holding
13
New
–
Increased
3
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$10.7M
2
ALKS icon
Alkermes
ALKS
+$26.2K
3
NXTC icon
NextCure
NXTC
+$753

Top Sells

Rank Stock Value
1
ENTA icon
Enanta Pharmaceuticals
ENTA
+$29.2M
2
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
+$6.9M
3
IVC
Invacare Corporation
IVC
+$4.24M
4
TVTX icon
Travere Therapeutics
TVTX
+$3.33M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$2.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.8B
$44.3M 15.35%
204,812
-2,475
-1% -$486K
REGN icon
2
Regeneron Pharmaceuticals
REGN
$78.5B
$43.6M 15.13%
69,080
-4,063
-6% -$2.5M
ENTA icon
3
Enanta Pharmaceuticals
ENTA
$366M
$42.2M 14.63%
564,102
-372,675
-40% -$29.2M
MCK icon
4
McKesson
MCK
$100B
$38.9M 13.49%
156,424
-8,167
-5% -$1.79M
ALKS icon
5
Alkermes
ALKS
$8.22B
$33.6M 11.64%
1,442,965
+998
+0.1% +$26.2K
EXEL icon
6
Exelixis
EXEL
$13.3B
$28.5M 9.87%
1,557,119
+557,119
+56% +$10.7M
TARO
7
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$27M 9.37%
538,967
-6,616
-1% -$371K
BIIB icon
8
Biogen
BIIB
$30B
$24.7M 8.58%
103,053
-149
-0.1% -$38.3K
EGRX
9
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$5.42M 1.88%
106,487
-1,286
-1% -$66.6K
NXTC icon
10
NextCure
NXTC
$16.8M
$186K 0.06%
2,586
+9
+0.3% +$753
TVTX icon
11
Travere Therapeutics
TVTX
$5.2B
– –
-137,203
Closed -$3.33M
IVC
12
DELISTED
Invacare Corporation
IVC
– –
-891,259
Closed -$4.24M
SRGA
13
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
– –
-211,098
Closed -$6.9M

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q4 2021 Portfolio in Review

As of Q4 2021, Krensavage Asset Management held 13 positions worth $288M, down 9.6% from $319M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Krensavage Asset Management withdrew a net $38.3M in Q4 2021, closing 3 positions and reducing 7 holdings. Its most notable exit was Surgalign Holdings, Inc. Common Stock, an estimated $6.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Krensavage Asset Management added an estimated $10.7M to Exelixis.

  • Krensavage Asset Management added most to Exelixis in Q4 2021, an estimated $10.7M increase.
  • Krensavage Asset Management's biggest Q4 2021 reduction was Enanta Pharmaceuticals, cutting an estimated $29.2M.
  • Krensavage Asset Management fully exited Surgalign Holdings, Inc. Common Stock in Q4 2021, selling an estimated $6.9M.
  • Krensavage Asset Management's ten largest holdings make up 100% of its $288M portfolio in Q4 2021.
  • Krensavage Asset Management opened 0 new positions and closed 3 in Q4 2021.
  • Krensavage Asset Management's portfolio value fell 9.6% quarter-over-quarter to $288M.

Based on Krensavage Asset Management's 13F filing for Q4 2021, filed 15 Feb 2022.